Heike Brötz-Oesterhelt

Dr. Heike Brötz-Oesterhelt


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
SHSimon Heilbronner
Simon Heilbronner
BKBernhard Krismer
Bernhard Krismer
HBHeike Brötz-Oesterhelt
Heike Brötz-Oesterhelt
APAndreas Peschel
Andreas Peschel

31 July 2024 in Nature
Verified
Journal Article
Closed access
PDF file
KLKim Lewis
Kim Lewis
RLRichard E. Lee
Richard E. Lee
HBHeike Brötz-Oesterhelt
Heike Brötz-Oesterhelt
SHSebastian Hiller
Sebastian Hiller
MRMarina V. Rodnina
Marina V. Rodnina
IWIngo Wohlgemuth
Ingo Wohlgemuth

4 April 2017 in Natural Product Reports
Verified
Journal Article
Open access
PDF file
IMI. T. Malik
I. T. Malik
HBHeike Brötz-Oesterhelt
Heike Brötz-Oesterhelt
Natural products targeting the bacterial Clp protease unravel key interfaces for protein–protein–interaction and long-distance conformational control.

26 February 2016 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
KFKirsten Famulla
Kirsten Famulla
PSPeter Sass
Peter Sass
IMImran Malik
Imran Malik
TATatos Akopian
Tatos Akopian
OKOlga Kandror
Olga Kandror
HBHeike Brötz-Oesterhelt
Heike Brötz-Oesterhelt
Summary: The Clp protease complex in Mycobacterium tuberculosis is unusual in its composition, functional importance and activation mechanism. Whilst most bacterial species contain a single ClpP protein that is dispensable for normal growth, mycobacteria have two ClpPs, ClpP1 and ClpP2, which are essential for viability and together form the ClpP1P2 tetradecamer. Acyldepsipeptide antibiotics of the ADEP class inhibit the growth of Gram‐positive firmicutes by activating ClpP and causing unregulated protein degradation. Here we show that, in contrast, mycobacteria are killed by ADEP through inhibition of ClpP function. Although ADEPs can stimulate purified M. tuberculosis ClpP1P2 to degrade larger peptides and unstructured proteins, this effect is weaker than for ClpP from other bacteria and depends on the presence of an additional activating factor (e.g. the dipeptide benzyloxycarbonyl‐leucyl‐leucine in vitro) to form the active ClpP1P2 tetradecamer. The cell division protein FtsZ, which is a particularly sensitive target for ADEP‐activated ClpP in firmicutes, is not degraded in mycobacteria. Depletion of the ClpP1P2 level in a conditional Mycobacterium bovis BCG mutant enhanced killing by ADEP unlike in other bacteria. In summary, ADEPs kill mycobacteria by preventing interaction of ClpP1P2 with the regulatory ATPases, ClpX or ClpC1, thus inhibiting essential ATP‐dependent protein degradation.

6 May 2019 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
NSNadine Anna Schilling
Nadine Anna Schilling
ABAnne Berscheid
Anne Berscheid
JSJohannes Schumacher
Johannes Schumacher
JSJulian Sigfried Saur
Julian Sigfried Saur
MKMartin Christoph Konnerth
Martin Christoph Konnerth
SGStephanie Grond
Stephanie Grond
Lugdunin, a novel thiazolidine cyclopeptide, exhibits micromolar activity against methicillin‐resistant Staphylococcus aureus (MRSA). For structure–activity relationship (SAR) studies, synthetic analogues obtained from alanine and stereo scanning as well as peptides with modified thiazolidine rings were tested for antimicrobial activity. The thiazolidine ring and the alternating d‐ and l‐amino acid backbone are essential. Notably, the non‐natural enantiomer displays equal activity, thus indicating the absence of a chiral target. The antibacterial activity strongly correlates with dissipation of the membrane potential in S. aureus. Lugdunin equalizes pH gradients in artificial membrane vesicles, thereby maintaining membrane integrity, which demonstrates that proton translocation is the mode of action (MoA). The incorporation of extra tryptophan or propargyl moieties further expands the diversity of this class of thiazolidine cyclopeptides.

5 May 2020 in ACS Infectious Diseases
Verified
Journal Article
Closed access
JBJayesh Arun Bafna
Jayesh Arun Bafna
ESEulalia Sans
Eulalia Sans
SASilvia Acosta-Gutierrez
Silvia Acosta-Gutierrez
IBIgor Bodrenko
Igor Bodrenko
DHDaniel HörÖmPölI
Daniel HörÖmPölI
MCMatteo Ceccarelli
Matteo Ceccarelli